The Helsinki-based company said it will use the funds to support further development of its AI-based digital pathology platform.

The firm touted a new clinical chemistry and immunoassay instrument and brain health assays in its diagnostics business during a call with investors on Friday morning.

A panel discussion at the Association for Diagnostics & Laboratory Medicine this week tackled questions around coding, reimbursement, and regulation of AI-based tests.

The firm increased its full-year guidance to a new range of $1.34 billion to 1.36 billion from a previous range of $1.30 billion to $1.32 billion.

The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.

This story has been updated to include comments from Labcorp's Q2 2026 earnings call. NEW YORK – Laboratory Corporation of America reported Thursday morning that its second-quarter revenue jumped 6 ...

Staffing is an issue for the clinical lab industry writ large, but rapid growth in demand and quickly changing technology has made liquid biopsies a particularly tricky area.

HHS OIG issued five recommendations, including refunding the federal government $18.5 million, as well as additional refunds for other potential overpayments.

The platform combines machine learning and sample preparation techniques with the firm's proprietary Raman spectral databases.

The partners are also working together to validate the company's molecular testing technologies in various settings.